Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer

Dou Zhang; Fanming Kong; Fangfang Gao; Longhui Li; Yangyueying Liang; Minghui Yu; Lu Zhao; Na Wang; Yingjie Jia

doi:10.1016/j.heliyon.2023.e22913

Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer

Heliyon. 2023 Nov 28;10(1):e22913. doi: 10.1016/j.heliyon.2023.e22913. eCollection 2024 Jan 15.

Authors

Dou Zhang^{1

2}, Fanming Kong^{1

2}, Fangfang Gao³, Longhui Li^{1

2}, Yangyueying Liang^{1

2}, Minghui Yu^{1

2}, Lu Zhao^{1

2}, Na Wang^{1

2}, Yingjie Jia^{1

2}

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Anshanxi Road, Nankai District, 300193, Tianjin, China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, China.
³ Department of Pediatrics, Tianjin Medical University General Hospital, Anshan Road, Tianjin, 300052, China.

Abstract

Objective: Exploring the clinical efficacy of camrelizumab in combination with first-line chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC).

Methods: The clinical data of 35 patients with ES-SCLC who received camrelizumab combined with EC or EP regimen in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from January 2020 to January 2023 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were OS, ORR and DCR. SPSS 25.0 software was used for statistical analysis, Kaplan-Meier curve and Log-Rank test analysis, and survival curve was drawn.

Results: The median PFS of 35 patients with SCLC was 7.4 months (95 % CI 6.75-9.81 months), .and the median OS was 12.5 months (95% CI,11.71-16.90 months). The ORR and DCR were 65.7 % and 74.3 %, respectively. Adverse events (AEs) were mainly concentrated in grade 1-2, and the probability of occurrence of grade 3 or above was low. Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) was the most common, followed by nausea &vomit and anemia. The other common AEs included abnormal thyroid function, decreased neutrophil count, skin rash and leucopenia.

Conclusion: Camrelizumab in combination with first-line chemotherapy regimens prolonged OS and PFS in SCLC patients and showed efficacy and safety in real-world data.

Keywords: Camrelizumab; Chemotherapy; Small-cell lung cancer.